HRP20030628A2 - The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment - Google Patents

The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment Download PDF

Info

Publication number
HRP20030628A2
HRP20030628A2 HR20030628A HRP20030628A HRP20030628A2 HR P20030628 A2 HRP20030628 A2 HR P20030628A2 HR 20030628 A HR20030628 A HR 20030628A HR P20030628 A HRP20030628 A HR P20030628A HR P20030628 A2 HRP20030628 A2 HR P20030628A2
Authority
HR
Croatia
Prior art keywords
hydrogen
alkyl
image
mammal
alkyl group
Prior art date
Application number
HR20030628A
Other languages
English (en)
Croatian (hr)
Inventor
Hegele-Hartung Christa
Hess-Stumpp Holger
M. Beier Henning
Krusche Claudia
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/801,925 external-priority patent/US20020143000A1/en
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of HRP20030628A2 publication Critical patent/HRP20030628A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
HR20030628A 2001-01-09 2002-01-09 The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment HRP20030628A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75628601A 2001-01-09 2001-01-09
US09/801,925 US20020143000A1 (en) 2001-01-09 2001-03-09 Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
PCT/IB2002/001764 WO2002067910A2 (en) 2001-01-09 2002-01-09 The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment

Publications (1)

Publication Number Publication Date
HRP20030628A2 true HRP20030628A2 (en) 2005-06-30

Family

ID=27116200

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030628A HRP20030628A2 (en) 2001-01-09 2002-01-09 The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment

Country Status (24)

Country Link
US (1) US20040152684A1 (enExample)
EP (1) EP1365765B1 (enExample)
JP (1) JP2004520411A (enExample)
CN (1) CN1244329C (enExample)
AR (1) AR032390A1 (enExample)
AT (1) ATE367817T1 (enExample)
AU (1) AU2002253488B2 (enExample)
BG (1) BG107977A (enExample)
BR (1) BR0206367A (enExample)
CA (1) CA2433776A1 (enExample)
CZ (1) CZ20031864A3 (enExample)
DE (1) DE60221359T2 (enExample)
DK (1) DK1365765T3 (enExample)
EE (1) EE200300321A (enExample)
ES (1) ES2290284T3 (enExample)
HR (1) HRP20030628A2 (enExample)
HU (1) HUP0302632A2 (enExample)
IL (1) IL156729A0 (enExample)
MX (1) MXPA03006156A (enExample)
NO (1) NO20033125L (enExample)
NZ (1) NZ526908A (enExample)
PL (1) PL361689A1 (enExample)
SK (1) SK8612003A3 (enExample)
WO (1) WO2002067910A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) * 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
EP3501533B1 (en) * 2014-12-22 2025-07-09 Ferring B.V. Obe001 for use in the treatment in implantation and pregnancy in women undergoing assisted reproductive technologies
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3533175A1 (de) * 1985-09-13 1987-03-19 Schering Ag Antigestagene zur verschiebung der endometrialen reifung
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE19860719A1 (de) * 1998-12-23 2000-06-29 Schering Ag Neue Testosteronderivate und ihre Verwendung zur Langzeittherapie von Androgen-abhängigen Erkrankungen

Also Published As

Publication number Publication date
US20040152684A1 (en) 2004-08-05
ES2290284T3 (es) 2008-02-16
BR0206367A (pt) 2003-12-23
BG107977A (bg) 2004-08-31
IL156729A0 (en) 2004-02-08
NO20033125L (no) 2003-09-09
HK1065953A1 (en) 2005-03-11
WO2002067910A2 (en) 2002-09-06
ATE367817T1 (de) 2007-08-15
CZ20031864A3 (en) 2004-03-17
DK1365765T3 (da) 2007-10-29
DE60221359D1 (de) 2007-09-06
WO2002067910A3 (en) 2003-02-06
NZ526908A (en) 2005-07-29
CA2433776A1 (en) 2002-09-06
EP1365765A2 (en) 2003-12-03
EP1365765B1 (en) 2007-07-25
HUP0302632A2 (hu) 2003-11-28
DE60221359T2 (de) 2008-04-17
CN1496263A (zh) 2004-05-12
NO20033125D0 (no) 2003-07-08
SK8612003A3 (en) 2004-03-02
PL361689A1 (en) 2004-10-04
AU2002253488B2 (en) 2007-02-15
EE200300321A (et) 2003-10-15
AR032390A1 (es) 2003-11-05
JP2004520411A (ja) 2004-07-08
MXPA03006156A (es) 2003-09-16
CN1244329C (zh) 2006-03-08

Similar Documents

Publication Publication Date Title
Austin et al. Effect of duration of dominance of the ovulatory follicle on onset of estrus and fertility in heifers
Sitruk-Ware et al. Contraception technology: past, present and future
Croxatto et al. Mechanisms of action of emergency contraception
Gemzell-Danielsson et al. Emergency contraception—mechanisms of action
Thatcher et al. Strategies for improving fertility in the modern dairy cow
TW201105330A (en) Pharmaceutical composition and treatment method for emergency contraception
CA2674325A1 (en) Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
Blithe Pipeline for contraceptive development
Costabile et al. A prospective randomized study comparing intramuscular progesterone and 17α-hydroxyprogesterone caproate in patients undergoing in vitro fertilization–embryo transfer cycles
US20020143000A1 (en) Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
Saunders Effects of sex steroids and related compounds on pregnancy and on development of the young.
Lamb et al. Reproductive endocrinology and hormonal control of the estrous cycle
HRP20030628A2 (en) The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
AU2002253488A1 (en) The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
Gemzell-Danielsson et al. Mechanisms of action of mifepristone when used for emergency contraception
JP3054780B2 (ja) 受精の阻止及び防止方法
Fisk et al. Lack of effect of high-dose antioestrogen on the maturation and in-vitro fertilization of human oocytes
Risso et al. The GnRH antagonist acyline prevented ovulation, but did not affect ovarian follicular development or gestational corpora lutea in the domestic cat
Yeko et al. The effect of aging on tubal function and ectopic pregnancy
Abu-Musa et al. Artificial endometrial preparation for oocyte donation using synthetic estrogen and progestogen
Capuzzo et al. The use of progestins to prevent the LH surge in IVF cycles
Risley Progestin regulation of follicular dynamics in beef cattle
Farman et al. Influence of estrogen, progesterone and their synthetic derivatives on ovarian functions
Darwash Effects of melengestrol acetate on postpartum reproductive activity of the dairy cow
HK1065953B (en) The use of antigestagens in manufacturing a medicament for inhibiting the occurrence of advanced endometrium maturation in a female mammal

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

OBST Application withdrawn